AstraZeneca PLC (AZN.L)
22 Nov 2017
LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.
The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:
BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca
* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA Source text for Eikon:
(This version of the Nov.15 story corrects the spelling of the drug in paragraphs 8, 9)
LONDON, Nov 15 AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.
* Says pricing Fasenra below the treatment cost of all other biologics in severe asthma
* Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
Nov 14 Anglo-Swedish pharmaceutical firm AstraZeneca Plc on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older.
* FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1 Source text for Eikon: Further company coverage:
NEW YORK Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.